UYMG's Metropolitan Computing Corporation.
Videos; Presses, Engineers, Patents & Software http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65214332
MCC/100% Owned By UYMG
Headquartered in East Hanover, New Jersey MCC /Legacy a 25 year old company was founded in 1985 to design, engineer, market, and service instrumentation equipment and software systems for increased efficiency within the pharmaceutical industry. The company continues to serve those various markets segments in need of instrumentation and data acquisition systems for pharmaceutical solid dosage, R&D, scale up (clinical Batch) and production.
MCC occupies a unique niche within a very large and healthy industry. The development and production of pharmaceutical grade tablets, both patented and generic, is capital intensive, highly profitable, and global. The players are subject to an exhausting degree of regulatory oversight as well as political uncertainty. However this outside scrutiny plays right into the strengths of MCC. The extensive drug approval process conducted by the FDA forces Pharma to detail the exact production process, as well as the specific components and dimensions of each tablet. What this means is that a drug company must reproduce the exact tablet that has been approved, each and every time, without error.
Throughout the course of a production run of tablets numbering in the tens of millions, the forces acting upon the components of the process (active and inactive powders, moving machine parts, and various sensors) are tremendous. Production takes place at very high speeds and quite often involves expensive and scarce ingredients. All of these factors place an inordinate amount of stress upon all the hardware and software systems involved in the process. For these reasons the industry must be extremely sensitive to the quality and reliability of the equipment it employs. It must be certain that any and all vendors are fully vetted and that their goods and services fit seamlessly within the process that leaves virtually no room for error.
For the past 25 years MCC has penetrated this difficult market and proven itself a worthy vendor to the industry by designing robust products to assist the industry in its efforts to gather rapidly streaming data and maintain critical tight production tolerances. Anticipating an increase in regulatory scrutiny, the company will become more valuable to an industry within which it has and continues to do business with the following firms: Pfizer, Merck, Bristol Meyers, Amgen, Bend Reasearch,Purdue Pharma,Hoffman Laroche, ISP,Boeringer Ingelheim, Exelixix, Watson Labs, Aqualon, Astra Zeneca, Schering-Plough, Novartis, Abbott Labs, JCMCO, Mendel Company, Cobalt Pharma, Medelpharm, Patheon,Sanofi-Aventis,Barr Labs, Covidien Pharma, Forest labs, Azopharma, and Genzyme.
Expecting News and Fins next week.